The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma

Eikesdal, Hans Petter; Schem, Baard-Christian; Mella, Olav; Dahl, Olav

doi:10.1016/s0360-3016(99)00451-4

Cited by 28 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All resulted in an enhancement of the heat response. This outcome was time and schedule dependent, with the maximum response generally observed if the heat was started 1 to 6 hours after VDA administration (78,80,81,99,124,212,214,215), corresponding to the maximal reduction in blood flow in those studies. As to the exact mechanism responsible for this enhancement, there is evidence for both an improved tumor heating (78,124,214) and a decrease in tumor pH (124-127).…”

Section: Combining Vtas With Other Therapiesmentioning

confidence: 89%

See 1 more Smart Citation

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

2006

View full text Add to dashboard Cite

A functional vascular supply is critical for the continued growth and development of solid tumors. It also plays a major role in metastatic spread of tumor cells. This importance has led to the concept of targeting the vasculature of the tumor as a form of cancer therapy. Two major types of vasculartargeting agent (VTA) have now emerged: those that prevent the angiogenic development of the neovasculature of the tumor and those that specifically damage the already established tumor vascular supply. When used alone neither approach readily leads to tumor control, and so, for VTAs to be most successful in the clinic they will need to be combined with more conventional therapies. However, by affecting the tumor vascular supply, these VTAs should induce pathophysiologic changes in variables, such as blood flow, pH, and oxygenation. Such changes could have negative or positive influences on the tumor response to more conventional therapies. This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy.

show abstract

Section: Combining Vtas With Other Therapiesmentioning

confidence: 89%

“…Numerous studies have examined the combination of VDAs and heat. The VDAs include TNF (74,75), ATO (80,212), vinblastine (78), FAA (81,124,213), DMXAA (99), and CA4P (78,214,215). All resulted in an enhancement of the heat response.…”

Section: Combining Vtas With Other Therapiesmentioning

confidence: 99%

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

2006

View full text Add to dashboard Cite

show abstract

“…The cells in this niche may continue or restart to grow causing tumor recurrence. In a heterotopic rat glioma model, blood flow in subcutaneous tumors dropped to about half of the initial tumor blood flow during the first 110 min after administration of CA4P (Eikesdal et al, 2000). However, treatment with CA4P at a dose of 50 mg/kg did not significantly affect tumor growth in comparison to controls.…”

Section: Vascular Disrupting Agentsmentioning

confidence: 85%

Future Perspectives of Enhancing the Therapeutic Efficacy of Epidermal Growth Factor Receptor Inhibition in Malignant Gliomas

Karpel‐Massler¹,

Halatsch²

2012

Novel Therapeutic Concepts in Targeting Glioma

View full text Add to dashboard Cite

“…As a promising adjuvant anticancer therapy for human patients, CA4P has been entered into several single and multiple administration dose‐escalation and toxicity studies in rodent models . In these species CA4P is consistently administrated through intraperitoneal (i.p.)…”

Section: Adverse Events Of Ca4p Administration In Experimental Animalmentioning

confidence: 99%

“…Doses ranging from 10 to 100 mg kg −1 have been tested extensively as single and repeated administration and in both nontumour‐bearing and tumour‐bearing rodents . Only few adverse reactions have been reported in these species.…”

Section: Adverse Events Of Ca4p Administration In Experimental Animalmentioning

confidence: 99%

Combretastatin A4‐phosphate and its potential in veterinary oncology: a review

Abma

Daminet

Smets

et al. 2015

Vet Comparative Oncology

View full text Add to dashboard Cite

For many years, research on anticancer therapy has focussed almost exclusively on targeting cancer cells directly, to selectively kill them or restrict their growth. But limited advances in this strategy have led researchers to shift their attention to other potential targets. Active research is now on-going on targeting tumour stroma. Vascular disrupting agents (VDAs) appear a promising class of anticancer drugs that are currently under investigation as a sole or combined therapy in human cancer patients. This article will briefly touch on the history and biology of combretastatin A4-phosphate (CA4P) as a typical example of VDAs and will concentrate on the side effects that can be expected when used in veterinary patients. Particularly, the pathogenesis of these side effects and how they may be prevented and/or treated will be discussed. The purpose of this article is to illustrate the potentials of CA4P as anticancer therapy in veterinary oncology patients.

show abstract

The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma

Cited by 28 publications

References 30 publications

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies

Future Perspectives of Enhancing the Therapeutic Efficacy of Epidermal Growth Factor Receptor Inhibition in Malignant Gliomas

Combretastatin A4‐phosphate and its potential in veterinary oncology: a review

Contact Info

Product

Resources

About